A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >-12 to <18 Years of Age, and Weigh >-35 kg
Clinical Trial Grant
Administered By
Pediatrics, Infectious Diseases
Awarded By
Merck Sharp & Dohme
Start Date
October 8, 2020
End Date
January 15, 2022
Administered By
Pediatrics, Infectious Diseases
Awarded By
Merck Sharp & Dohme
Start Date
October 8, 2020
End Date
January 15, 2022